Products for Research Use Only

CBT-295

CAT: 0804-HY-169004-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-169004-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy[1].
UNSPSC
12352005
Target
Interleukin Related; TGF-beta/Smad
Type
Reference compound
Related Pathways
Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/cbt-295.html
Purity
99.34
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1C=C(C)N(CCCCC)C2=NC(C3=CC=C(Cl)C=C3)=CN12
Molecular Formula
C18H20ClN3O
Molecular Weight
329.82
References & Citations
[1]Roy S, et al. Effect of an Autotaxin Inhibitor, 2- (4-Chlorophenyl) -7-methyl-8-pentylimidazo [1, 2-a] Pyrimidin-5 (8 H) -one (CBT-295), on Bile Duct Ligation-Induced Chronic Liver Disease and Associated Hepatic Encephalopathy in Rats[J]. ACS Pharmacology & Translational Science, 2024.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported